Table 1.

Selected aspects of pharmacokinetics and drug metabolism

	Canagliflozin	Empagliflozin	Dapagliflozin	Ertugliflozin
Half-life (hours)	10.6–13.1	12.4	8–12.9	16.6
Dosing adjustment in patients with impaired renal function	eGFR 45–60 mL/min/1.73 m2, use 100 mg; eGFR <45 mL/min/1.73 m2, do not initiate; contraindicated eGFR <30 mL/min/1.73 m2	eGFR <45 mL/min/1.73 m2, do not initiate; contraindicated in severe renal impairment/dialysis	eGFR <60 mL/min/1.73 m2, do not initiate; contraindicated eGFR <30 mL/min/1.73 m2	eGFR <60 mL/min/1.73 m2, do not initiate; contraindicated eGFR <30 mL/min/1.73 m2
Metabolism: UGT isoforms	UGT1A9, UGT2B4	UGT2B7, UGT1A3, UGT1A8, UGT1A9	UGT1A9	UGT1A9, UGT2B7
Metabolism: other pathways	CYP3A4 (∼7%)			Pgp substrate

eGFR, estimated glomerular filtration rate; Pgp, permeability glycoprotein.